ZURICH, Nov. 09, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $3.29 per share, representing a 20% premium to the last closing price of the Company's common shares on November 6, 2026..

苏黎世，2026年11月9日（环球电讯社）——临床阶段生物制药公司NewcelX Ltd.（纳斯达克股票代码：NCEL）今日宣布，该公司已签订证券购买协议，进行非公开发行，发行价格为每股3.29美元，较该公司普通股在2026年11月6日的最后收盘价溢价20%。

Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 471,125 common shares and one series of warrants to purchase an aggregate of 353,344 common shares at an exercise price of $3.75 per share, which is 137% of the last closing price of the Company's common shares on November 6, 2026..

根据证券购买协议的条款，公司正在出售总计471,125股普通股，以及一系列认股权证，该等认股权证可按每股3.75美元的行权价格购买总计353,344股普通股，该行权价格为该公司普通股在2026年11月6日最后收盘价的137%。

The offering includes participation from existing shareholders and is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

本次发行包括现有股东的参与，预计将于2026年11月23日或左右完成，但须满足惯常的交割条件。

The Company intends to use the net proceeds from the offering, together with its current cash position, and previously announced $25 million equity line, primarily to advance NCEL-101, NewcelX's lead program for type 1 diabetes, in collaboration with Eledon Pharmaceuticals, and specifically to initiate the FDA-required IND-enabling toxicology study, advance cell manufacturing capabilities and support preparations for the planned Phase 1/2a clinical trial in 2027, and for working capital and general corporate purposes..

本公司拟将本次发行的净收益，连同其现有现金状况及此前宣布的2,500万美元股权额度，主要用于与Eledon Pharmaceuticals合作推进NewcelX的核心项目NCEL-101（针对1型糖尿病），具体包括启动FDA要求的IND申报前毒理学研究、提升细胞生产能力并支持为计划于2027年开展的1/2a期临床试验所做的准备工作，以及用于营运资金和一般公司用途。

“We are pleased to welcome this distinguished group of healthcare investors, whose experience, reputation, and long-term perspective bring significant value beyond their financial investment,”

“我们很高兴欢迎这群杰出的医疗健康领域投资者，他们的经验、声誉和长期视角为其财务投资之外带来了显著价值。”

said Ronen Twito, CEO & Executive Chairman of NewcelX

NewcelX 首席执行官兼执行董事长罗南·图维托表示

. “We believe that their participation, together with involvement of The Crushing T1 Foundation, represents a strong vote of confidence in our technology, strategy, and clinical potential. Importantly, the investment at a substantial premium to the prevailing market price underscores the conviction of these investors in the long-term value of NewcelX.

“我们相信，他们的参与以及Crushing T1基金会的介入，代表了对我们的技术、战略和临床潜力的强烈信心。重要的是，此次投资以较现行市场价格大幅溢价进行，凸显了这些投资者对NewcelX长期价值的坚定信念。”

This financing comes at an important stage as we advance toward initiating our IND-enabling studies following our successful Pre-IND meeting with the FDA and prepare for our planned Phase 1/2a clinical trial in 2027, in collaboration with Eledon Pharmaceuticals.”.

“在我们与美国食品药品监督管理局（FDA）成功召开预 IND 会议后，正推进启动 IND enabling 研究，并与 Eledon Pharmaceuticals 合作筹备计划于 2027 年开展的 1/2a 期临床试验，此次融资恰逢这一重要阶段。”

The securities described above are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and Regulation D promulgated thereunder and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

上述证券正根据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条及其下颁布的D条例以私募方式发行，且未根据《证券法》或适用的州证券法进行注册。因此，除非依据有效的注册声明或符合《证券法》及此类适用州证券法注册要求的豁免情形，否则不得在美国境内要约或出售该等证券。

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或征求购买本次发行证券的要约，在任何州或其他司法管辖区，在根据该州或其他司法管辖区的证券法进行注册或资格认定之前，若此类要约、征求或销售行为属违法，则不得在这些地区销售上述证券。

About NewcelX

关于 NewcelX

NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement.

NewcelX 是一家创新的生物制药公司，专注于开发用于1型糖尿病的变革性干细胞衍生疗法。基于经过验证的人多能干细胞（hPSC）平台，公司的核心项目 NCEL-101 旨在通过可规模化、现成的细胞替代疗法恢复功能性胰岛素生产。

NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs..

NewcelX 正在推进一种针对 1 型糖尿病的综合治疗方法，整合细胞疗法、免疫保护和转化科学，以满足关键的未满足医疗需求。

Social Media:

社交媒体：

LinkedIn

领英

,

，

Facebook

脸书

,

，

X

X

,

，

Instagram

Instagram

Website:

网站：

www.newcelx.com

www.newcelx.com

Forward-Looking Statements

前瞻性陈述

This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom, the advancement and development of NCEL-101, the initiation and timing of IND-enabling studies, its manufacturing capabilities and scalability, and the timing and commencement of its planned Phase 1/2a clinical trial, including its plans to commence such trial in 2027.

本新闻稿包含根据1995年《私人证券诉讼改革法案》及其他适用证券法律定义的明示或暗示的前瞻性陈述。例如，NewcelX在讨论以下事项时使用了前瞻性陈述：本次发行的时间安排及完成、与本次发行相关的惯例交割条件的满足、募集资金的预期用途、NCEL-101的推进与开发、支持新药临床试验申请（IND）的研究的启动与时间安排、其生产能力及可扩展性，以及其计划的1/2a期临床试验的时间安排与启动，包括其于2027年启动该试验的计划。

These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the regulatory pathways that NewcelX may elect to utilize in seeking European Medicines Agency, the FDA, and other regulatory approvals; its ability to drive revenue growth, enhance research and development capabilities, and improve financial performance is subject to uncertainties; that its financial position raises substantial doubt about its ability to continue as a going concern; its ability to maintain listing and effectively comply with the listing requirements of the Nasdaq; changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials, including its expectations regarding the timing of commencing further c.

这些前瞻性陈述及其影响基于NewcelX管理层的当前预期，并受多种因素和不确定性的影响，可能导致实际结果与前瞻性陈述中描述的结果存在重大差异。除其他因素外，以下因素可能导致实际结果与前瞻性陈述中描述的结果存在重大差异：NewcelX在寻求欧洲药品管理局、美国食品药品监督管理局（FDA）及其他监管机构批准时可能选择的监管路径；其推动收入增长、增强研发能力以及改善财务表现的能力存在不确定性；其财务状况令人对其持续经营能力产生重大疑虑；其维持纳斯达克上市地位并有效遵守上市要求的能力；技术和市场需求的变化；在启动或完成临床试验方面可能出现的延误或障碍，包括其对启动进一步临床试验时间的预期。

Investor Contact

投资者联系

KCSA Strategic Communications

KCSA战略传播

Valter Pinto, Managing Director

瓦尔特·平托，总经理

PH: (212) 896-1254

电话：(212) 896-1254

NewCelX@kcsa.com

NewCelX@kcsa.com

Company Contact

公司联系方式

Sarah Bazak

莎拉·巴扎克

InvestorRelations@newcelx.com

投资者关系@newcelx.com